



**Faculty of Resource Science and Technology**

**Pharmacophore Modelling Analysis and Synthesis of Vanillin Derivatives  
as Neuraminidase Inhibitors of Influenza Virus and 3CL<sup>pro</sup> Inhibitors of  
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)**

**Law Woon Yi**

**Master of Science  
2022**

Pharmacophore Modelling Analysis and Synthesis of Vanillin Derivatives as  
Neuraminidase Inhibitors of Influenza Virus and 3CL<sup>pro</sup> Inhibitors of Severe  
Acute Respiratory Syndrome Coronavirus (SARS-CoV)

Law Woon Yi

A thesis submitted

In fulfillment of the requirements for the degree of Master of Science

(Organic Chemistry)

Faculty of Resource Science and Technology

UNIVERSITI MALAYSIA SARAWAK

2022

## DECLARATION

I declare that the work in this thesis was carried out in accordance with the regulations of Universiti Malaysia Sarawak. Except where due acknowledgements have been made, the work is that of the author alone. The thesis has not been accepted for any degree and is not concurrently submitted in candidature of any other degree.

.....

Signature

Name: Law Woon Yi

Matric No.: 19020150

Faculty of Resource Science and Technology

Universiti Malaysia Sarawak

Date :

## **ACKNOWLEDGEMENT**

First of all, I would like to express my sincere gratitude to my supervisor, Dr Mohd Razip Bin Asaruddin for all the guidance and advice which provided me a lot of support throughout the progress of research. The accomplishment of this research is greatly contributed by the help from Dr Mohd Razip Bin Asaruddin.

I would also like to thank Centre for Graduate Studies (CGS) for all the support, seminars and support throughout the writing of thesis. On top of that, I would like to convey my gratitude towards my laboratory partners, Miss Sophia Ann ak Suring, Mr Hanif Bin Mohd Teddy and Miss Nurina Asyura binti Mohd Yunus for all the help, support and guidance throughout my progress of research.

Furthermore, I would like to sincerely thank my parents, Mr Law Joon Chiew and Mdm Thian Li Moi for the support, love and care throughout the two years. I would also like to thank my husband, Dr Sim Song-Lin for the support and love to me throughout my Master programme. Last but not least, my uttermost gratitude goes to my siblings and family members for all the love and support.

## ABSTRACT

Influenza remain as global threat and public health concern over the years. For the past century, there were a number of significant influenza pandemics recorded, which were H1N1 Spanish flu (1918), the H2N2 Asian flu (1957), the H3N2 Hong Kong flu (1968), and the H1N1 swine flu (2009). Despite the fact that licensed drugs were available, antigenic drifts and shifts of influenza virus resulted in mutation of the virus, therefore the virus possess resistance towards available drugs. Thus, research in discovering more effective drugs or inhibitors against influenza virus is continuously necessary. Focus is given particularly to the discovery of neuraminidase inhibitors (NAIs) of influenza virus due to the important role of neuraminidase in facilitating the spread of virus. At the same time, severe acute respiratory syndrome coronavirus (SARS-CoV) also remain as a global threat due to the high rate of mutation and recombination. There were no licensed drugs available for SARS-CoV despite the numerous research being conducted, hence discovery of potent drugs or inhibitors for SARS-CoV become necessarily important. Focus is given particularly to the finding of 3CL<sup>pro</sup> inhibitors of SARS-CoV for the importance of 3CL<sup>pro</sup> in viral polyproteins processing and replicase complex activity controlling. Vanillin was reported in research for its biological activities, whereby the most important activity is the antiviral activity against NA. Research related to vanillin as NAIs are very potential and interesting, but considerably limited. Therefore, in this research, a list of Schiff base vanillin derivatives were evaluated and analysed for their potential as NAIs and 3CL<sup>pro</sup> inhibitors *via* computer-aided drug design (CADD), particularly ligand-based pharmacophore modelling, virtual screening and structure-based molecular docking. As a result, 7 out of 9 vanillin derivatives, labelled as A1 to A7, were concluded to possess potential as both NAIs and 3CL<sup>pro</sup> inhibitors. The 7 vanillin

derivatives successfully synthesized and characterized by Fourier Transform-Infrared spectroscopy (FT-IR).

**Keywords:** Coronavirus, docking, influenza, pharmacophore, vanillin

***Analisis Pemodelan Farmakofor dan Pembuatan Derivatif Vanillin Sebagai Perencat Neuraminidase Virus Influenza dan Perencat 3CL<sup>pro</sup> Koronavirus Sindrom Pernafasan Akut Teruk (SARS-CoV)***

**ABSTRAK**

*Influenza kekal sebagai ancaman global dan keprihatinan kesihatan dari awam untuk beberapa tahun. Pada abad yang lalu, terdapat beberapa pandemik influenza yang ketara direkodkan, termasuk Selesema Sepanyol H1N1 (1918), Selesema Asia H2N2 (1957), Selesema Hong Kong H3N2 (1968), dan Selesema babi H1N1 (2009). Walaupun ubat berdaftar tersedia, pergeseran antigenik virus influenza menyebabkan mutasi virus tersebut, oleh yang demikian virus tersebut mempunyai rintangan terhadap ubat yang ada. Oleh itu, penyelidikan dalam mencari ubat atau perencat yang lebih berkesan terhadap virus influenza adalah diperlukan secara berterusan. Fokus diberi khususnya kepada pencarian perencat neuraminidase (NAIs) virus influenza disebabkan oleh kepentingan peranan neuraminidase dalam membantu penyebaran virus. Pada masa yang sama, sindrom pernafasan akut teruk (SARS-CoV) juga kekal sebagai ancaman global disebabkan oleh kadar mutasi dan rekombinasi yang tinggi. Tiada ubat berdaftar tersedia untuk SARS-CoV walaupun banyak penyelidikan telah dijalankan, dengan itu pencarian ubat atau perencat yang berkesan untuk SARS-CoV menjadi amat penting. Fokus diberi khususnya kepada pencarian perencat 3CL<sup>pro</sup> SARS-CoV disebabkan oleh kepentingan 3CL<sup>pro</sup> dalam pemprosesan poliprotein viral dan pengawalan aktiviti kompleks replika. Vanillin telah dilaporkan dalam penyelidikan dari segi aktiviti biologikalnya, di mana aktiviti yang paling penting adalah aktiviti antivirus terhadap NA. Penyelidikan berkaitan dengan vanillin sebagai NAIs adalah berpotensi dan menarik, tetapi dikira terhad. Oleh itu, dalam penyelidikan ini, satu senarai derivatif vanillin Schiff base telah dinilai dan dianalisis dari segi potensi sebagai perencat NA dan 3CL<sup>pro</sup> melalui reka bentuk ubat berbantuan*

*komputer (CADD), khususnya pemodelan farmakofor berasaskan ligan, saringan maya, dan dok molekul berasaskan struktur. Akibatnya, 7 daripada 9 derivatif vanillin, dilabel sebagai A1 ke A7, disimpulkan sebagai perencat NA dan 3CL<sup>pro</sup> yang berpotensi. 7 derivatif vanillin tersebut berjaya disintesis dan dicirikan dengan Spektroskopi Inframerah-Transformasi Fourier.*

**Kata kunci:** *Koronavirus, dok, influenza, farmakofor, vanillin*



## TABLE OF CONTENTS

	<b>Page</b>
<b>DECLARATION</b>	i
<b>ACKNOWLEDGEMENT</b>	ii
<b>ABSTRACT</b>	iii
<b><i>ABSTRAK</i></b>	v
<b>TABLE OF CONTENTS</b>	vii
<b>LIST OF TABLES</b>	x
<b>LIST OF FIGURES</b>	xi
<b>LIST OF ABBREVIATIONS</b>	xxii
<b>CHAPTER 1: INTRODUCTION</b>	1
1.1 Research Background	1
1.2 Problem Statement	8
1.3 Objectives	9
<b>CHAPTER 2: LITERATURE REVIEW</b>	10
2.1 Influenza	10
2.1.1 Influenza Virus	11
2.1.2 The Structure of Influenza Virus	13
2.1.3 The Influenza Virus Replication Cycle	15
2.1.4 Pandemics of Influenza	18

2.1.5	Influenza Neuraminidase (NA)	21
2.1.6	Influenza Neuraminidase (NA) Inhibitors	26
2.2	Coronavirus	30
2.2.2	Life Cycle of SARS-CoV	42
2.2.3	SARS-CoV 3CL <sup>pro</sup> Inhibitors	44
2.3	Biological Activity of Vanillin	49
2.4	Computer-Aided Drug Design (CADD)	55
2.4.1	Pharmacophore Modelling	58
2.4.2	Virtual Screening	61
2.4.3	Pharmacophore-based Molecular Docking	62
2.5	Research Summary	66
<b>CHAPTER 3: MATERIALS AND METHODS</b>		<b>67</b>
3.1	Overview of CADD	67
3.2	Neuraminidase Inhibitors (NAIs) of Influenza Virus	68
3.2.1	Ligand-based Pharmacophore Modelling	68
3.2.2	Structure-based Molecular Docking	78
3.3	3CL <sup>pro</sup> Inhibitors of SARS-CoV	83
3.3.1	Ligand-based Pharmacophore Modelling	83
3.3.2	Structure-based Molecular Docking	85
3.4	Chemical Synthesis	89

3.5	Characterization of Synthesized Vanillin Derivatives	93
3.5.1	Thin-Layer Chromatography (TLC)	93
3.5.2	Fourier Transform-Infrared Spectroscopy (FT-IR)	94
<b>CHAPTER 4: RESULTS AND DISCUSSION</b>		<b>95</b>
4.1	Neuraminidase Inhibitors (NAIs) of Influenza Virus	95
4.1.1	Ligand-based Pharmacophore Modelling <i>via</i> LigandScout 4.3	95
4.1.2	Structure-based Molecular Docking	139
4.2	3CL <sup>pro</sup> inhibitors of SARS-CoV	150
4.2.1	Ligand-based Pharmacophore Modelling	150
4.2.2	Structure-based Molecular Docking	168
4.3	Chemical Synthesis	177
4.4	Characterizations of Synthesized Vanillin Derivatives	179
<b>CHAPTER 5: CONCLUSION AND RECOMMENDATIONS</b>		<b>196</b>
5.1	Conclusion	196
5.2	Recommendations	198
<b>REFERENCES</b>		<b>199</b>

## LIST OF TABLES

	<b>Page</b>
Table 2.1 Peptidomimetic compounds 6b, 6c and 6d possessing inhibitory activity against 3CL <sup>pro</sup> of SARS-CoV and MERS-CoV	47
Table 3.1 Training sets used to generate pharmacophore model, PM1	69
Table 3.2 Test sets used to validate PM1	71
Table 3.3 Training sets of 3CL <sup>pro</sup> inhibitors of SARS-CoV	84
Table 3.4 Synthetic route of 9 Schiff base vanillin derivatives	91
Table 4.1 3D structures of training sets for generation of PM1	96
Table 4.2 3D structures of test sets for validation of PM1	97
Table 4.3 Top 10 drug compounds with best fit in PM1	118
Table 4.4 3D structures of training sets for generation of PM2	122
Table 4.5 3D structures of test sets (vanillin derivatives) for evaluation in PM2	123
Table 4.6 Lipinski's rule of five of vanillin derivatives	148
Table 4.7 3D structures of training sets for generation of pharmacophore model	151

## LIST OF FIGURES

	<b>Page</b>
Figure 2.1 Structure of the Influenza Virion (National Institutes of Health, 2006)	14
Figure 2.2 The Influenza Virus Replication Cycle (Libretexts, n.d.)	16
Figure 2.3 Specific strains of influenza infection throughout the 20th century (Palese, 2004)	21
Figure 2.4 Four distinct structural domains of influenza NA (Mcauley et al., 2019)	22
Figure 2.5 An electron micrograph of a two-dimensional crystal array of NA heads (PDB: 4GZX) (Mcauley et al., 2019)	22
Figure 2.6 Structure of the complex between NA and sialic acid (PDB: 2BAT) (Yen et al., 2006)	24
Figure 2.7 NA active sites S1-S5 with Neu5Ac2en inhibitor (Gong et al., 2007)	24
Figure 2.8 Comparison of chemical structures of (A) DANA, (B) Zanamivir, and (C) Oseltamivir carboxylate	27
Figure 2.9 Comparison of chemical structures of (B) Zanamivir and (D) Laninamivir	28
Figure 2.10 Comparison of chemical structures of (A) DANA, (B) Zanamivir, (C) Oseltamivir carboxylate, and (E) Peramivir	28
Figure 2.11 Human Coronavirus OC16 (Jaiswal & Saxena, 2020)	31
Figure 2.12 Structure of a coronavirus (Sriwilaijaroen & Suzuki, 2020)	34
Figure 2.13 SARS-CoV genome and proteins (Tan et al., 2009)	36
Figure 2.14 Summary of SARS-CoV protein structures (Bartlam et al., 2007)	38

Figure 2.15	(a) The four domains of SARS-CoV PL <sup>pro</sup> (b) An overlay of SARS-CoV PL <sup>pro</sup> (blue) with USP7 (yellow, PDB: 4M5W) displaying the USP fold (B éz-Santos et al., 2015)	39
Figure 2.16	Catalytic centre of the active site of SARS-CoV PL <sup>pro</sup> , with the catalytic triad residues, Cys112, His273 and Asp287 (B éz-Santos et al., 2015)	40
Figure 2.17	Ribbon presentation of the SARS-CoV 3CL <sup>pro</sup> dimer (PDB code: 1Z1J) (Hsu et al., 2005)	41
Figure 2.18	The life cycle of SARS-CoV in host cell (Du et al., 2009)	42
Figure 2.19	(a) Free enzyme of SARS-CoV (b) SARS–lopinavir complex and (c) SARS–ritonavir complex (Nukoolkarn et al., 2008)	44
Figure 2.20	3CL <sup>pro</sup> active site and interactions with quinoline and saquinavir (Alexpandi et al., 2020)	46
Figure 2.21	Molecular docking of 5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl) isoflavone in the receptor-binding site of 3CL <sup>pro</sup> , whereby hydrogen bondings are shown in maroon colour (Tahir ul Qamar et al., 2020)	48
Figure 2.22	Chemical structure of vanillin	50
Figure 2.23	Different sources and synthesis route of vanillin (Arya et al., 2021)	51
Figure 2.24	The docked pose of MY21 in the active site of NA (Hariono et al., 2016)	53
Figure 2.25	Traditional process of drug discovery and development (Surabhi & Singh, 2018)	55
Figure 2.26	General representation of the workflow of CADD	56
Figure 2.27	General workflow of SBDD	58

Figure 2.28	A pharmacophore query comprising of different features (Qing et al., 2014)	59
Figure 2.29	Cyclin Dependent Kinase 2 (CDK2) with diaminopyrimidine inhibitor (PDB: 2FVD) (Chu et al., 2006)	64
Figure 2.30	Ligand, LIA299 or diaminopyrimidine inhibitor in the active site of 2FVD (Chu et al., 2006)	64
Figure 2.31	Pharmacophore model generated from the ligand, LIA299 or diaminopyrimidine inhibitor in the active site of 2FVD (Chu et al., 2006)	65
Figure 3.1	General overview of CADD (Asaruddin, 2016)	67
Figure 3.2	ChemDraw Pro 8.0 software to draw chemical structures	68
Figure 3.3	General flow process of generation of Pharmacophore Model 1, PM1	75
Figure 3.4	FDA-approved drugs from The Binding Database (Binding DB, n.d.)	76
Figure 3.5	Generation of Pharmacophore Model 2, PM2 and evaluation of Schiff base vanillin derivatives as potential NAIs based on model scores, matching features and pharmacophore fit values	77
Figure 3.6	N1 neuraminidase in complex with oseltamivir 1 from PDB (2HU0)	79
Figure 3.7	Generation of pharmacophore model of ligand, oseltamivir	79
Figure 3.8	Oseltamivir ligand and its pharmacophore model in the alignment perspective	80
Figure 3.9	Alignment of oseltamivir ligand with vanillin derivative	81
Figure 3.10	Shared feature pharmacophore, merged pharmacophores and interpolated overlapping features	81

Figure 3.11	Interactions between vanillin derivative and the active site of 2HU0 protein in comparison with oseltamivir ligand	82
Figure 3.12	Crystal structure of SARS-CoV M <sup>Pro</sup> in complex with an inhibitor I2, ENB (2D2D)	86
Figure 3.13	Generation of pharmacophore model of ligand, ENB	87
Figure 3.14	ENB ligand and its pharmacophore model in the alignment perspective	87
Figure 3.15	Alignment of ENB ligand with vanillin derivative	88
Figure 3.16	Shared feature pharmacophore, merged pharmacophores and interpolated overlapping features	88
Figure 3.17	Interactions between vanillin derivative and the active site of 2D2D in comparison with ENB ligand	89
Figure 3.18	Synthetic route of Schiff base vanillin derivative	90
Figure 3.19	General illustration of TLC to show the progress of reaction and purity	93
Figure 4.1	Conformation values, cluster ID and cluster size of training sets and test sets for PM1	98
Figure 4.2	Pharmacophore model 1 (PM1)	98
Figure 4.3	Matching features and pharmacophore fit values of training sets and test sets in PM1	99
Figure 4.4	Interaction, matching features and pharmacophore fit value between peramivir and PM1	100
Figure 4.5	Interaction, matching features and pharmacophore fit value between zanamivir and PM1	101



Figure 4.6	Interaction, matching features and pharmacophore fit value between A-315675 and PM1	102
Figure 4.7	Interaction, matching features and pharmacophore fit value between ((2-aminopropanamido)thazol-4-yl)acetic acid and PM1	103
Figure 4.8	Interaction, matching features and pharmacophore fit value between 4-(acetylamino)-3-guanidinobenzoic acid and PM1	104
Figure 4.9	Interaction, matching features and pharmacophore fit value between A-192558 and PM1	105
Figure 4.10	Interaction, matching features and pharmacophore fit value between AV5027 and PM1	106
Figure 4.11	Interaction, matching features and pharmacophore fit value between BCX1923 and PM1	107
Figure 4.12	Interaction, matching features and pharmacophore fit value between DANA and PM1	108
Figure 4.13	Interaction, matching features and pharmacophore fit value between GS4071 and PM1	109
Figure 4.14	Interaction, matching features and pharmacophore fit value between bisdemethoxycurcumin and PM1	110
Figure 4.15	Interaction, matching features and pharmacophore fit value between ganoderic acid and PM1	111
Figure 4.16	Interaction, matching features and pharmacophore fit value between 5,7,3',4'-tetra-O-methylquercetin and PM1	112
Figure 4.17	Interaction, matching features and pharmacophore fit value between baicalein and PM1	113

Figure 4.18	Interaction, matching features and pharmacophore fit value between geraniin and PM1	114
Figure 4.19	Interaction, matching features and pharmacophore fit value between baicalin and PM1	115
Figure 4.20	Interaction, matching features and pharmacophore fit value between 5,7-dihydroxy-4-oxo-2-(3,4,5-trihydroxyphenyl)chroman-3-yl-3,4,5-trihydroxycyclohexanecarboxylate and PM1	116
Figure 4.21	Conformation values, cluster ID and cluster sizes of training sets and test sets for PM2	124
Figure 4.22	Pharmacophore model 2, PM2	124
Figure 4.23	Matching features and pharmacophore fit values of training sets and test sets in PM2	125
Figure 4.24	Interaction, matching features and pharmacophore fit value between cefaclor and PM2	126
Figure 4.25	Interaction, matching features and pharmacophore fit value between methyldopa and PM2	126
Figure 4.26	Interaction, matching features and pharmacophore fit value between cefdinir and PM2	127
Figure 4.27	Interaction, matching features and pharmacophore fit value between cephalixin and PM2	128
Figure 4.28	Interaction, matching features and pharmacophore fit value between levodopa and PM2	128
Figure 4.29	Interaction, matching features and pharmacophore fit value between cangrelor and PM2	129

Figure 4.30	Interaction, matching features and pharmacophore fit value between cephadrine and PM2	129
Figure 4.31	Interaction, matching features and pharmacophore fit value between cyclacillin and PM2	130
Figure 4.32	Interaction, matching features and pharmacophore fit value between ampicillin and PM2	131
Figure 4.33	Interaction, matching features and pharmacophore fit value between argatroban and PM2	131
Figure 4.34	Interaction, matching features and pharmacophore fit value between A1 and PM2	132
Figure 4.35	Interaction, matching features and pharmacophore fit value between A2 and PM2	133
Figure 4.36	Interaction, matching features and pharmacophore fit value between A3 and PM2	133
Figure 4.37	Interaction, matching features and pharmacophore fit value between A4 and PM2	134
Figure 4.38	Interaction, matching features and pharmacophore fit value between A5 and PM2	135
Figure 4.39	Interaction, matching features and pharmacophore fit value between A6 and PM2	135
Figure 4.40	Interaction, matching features and pharmacophore fit value between A7 and PM2	136
Figure 4.41	Interaction, matching features and pharmacophore fit value between A8 and PM2	137

Figure 4.42	Interaction, matching features and pharmacophore fit value between A9 and PM2	137
Figure 4.43	Pharmacophore model, features and interactions of oseltamivir ligand in active site of 2HU0	140
Figure 4.44	Alignment of A1 to oseltamivir, shared feature pharmacophore model and interactions in active site of 2HU0	141
Figure 4.45	Alignment of A2 to oseltamivir, shared feature pharmacophore model and interactions in active site of 2HU0	142
Figure 4.46	Alignment of A3 to oseltamivir, shared feature pharmacophore model and interactions in active site of 2HU0	142
Figure 4.47	Alignment of A4 to oseltamivir, shared feature pharmacophore model and interactions in active site of 2HU0	143
Figure 4.48	Alignment of A5 to oseltamivir, shared feature pharmacophore model and interactions in active site of 2HU0	144
Figure 4.49	Alignment of A6 to oseltamivir, shared feature pharmacophore model and interactions in active site of 2HU0	144
Figure 4.50	Alignment of A7 to oseltamivir, shared feature pharmacophore model and interactions in active site of 2HU0	145
Figure 4.51	Alignment of A8 to oseltamivir, shared feature pharmacophore model and interactions in active site of 2HU0	146
Figure 4.52	Alignment of A9 to oseltamivir, shared feature pharmacophore model and interactions in active site of 2HU0	146
Figure 4.53	Conformation values, cluster ID and cluster size of training sets and test sets for generation of pharmacophore model	152

Figure 4.54	Generated pharmacophore model	152
Figure 4.55	Matching features and pharmacophore fit values of training sets and vanillin derivatives in pharmacophore model	153
Figure 4.56	Interaction, matching features and pharmacophore fit value between luteolin and pharmacophore model	154
Figure 4.57	Interaction, matching features and pharmacophore fit value between herbacetin and pharmacophore model	154
Figure 4.58	Interaction, matching features and pharmacophore fit value between pectolarin and pharmacophore model	155
Figure 4.59	Interaction, matching features and pharmacophore fit value between scutellarein and pharmacophore model	156
Figure 4.60	Interaction, matching features and pharmacophore fit value between rhoifolin and pharmacophore model	157
Figure 4.61	Interaction, matching features and pharmacophore fit value between amentoflavone and pharmacophore model	158
Figure 4.62	Interaction, matching features and pharmacophore fit value between hesperetin and pharmacophore model	159
Figure 4.63	Interaction, matching features and pharmacophore fit value between lycorine and pharmacophore model	160
Figure 4.64	Interaction, matching features and pharmacophore fit value between A1 and pharmacophore model	161
Figure 4.65	Interaction, matching features and pharmacophore fit value between A2 and pharmacophore model	161

Figure 4.66	Interaction, matching features and pharmacophore fit value between A3 and pharmacophore model	162
Figure 4.67	Interaction, matching features and pharmacophore fit value between A4 and pharmacophore model	163
Figure 4.68	Interaction, matching features and pharmacophore fit value between A5 and pharmacophore model	163
Figure 4.69	Interaction, matching features and pharmacophore fit value between A6 and pharmacophore model	164
Figure 4.70	Interaction, matching features and pharmacophore fit value between A7 and pharmacophore model	165
Figure 4.71	Interaction, matching features and pharmacophore fit value between A8 and pharmacophore model	165
Figure 4.72	Interaction, matching features and pharmacophore fit value between A9 and pharmacophore model	166
Figure 4.73	Pharmacophore model, features and interactions of ENB ligand in active site of 2D2D	168
Figure 4.74	Alignment of A1 to ENB, shared feature pharmacophore model and interactions in active site of 2D2D	170
Figure 4.75	Alignment of A2 to ENB, shared feature pharmacophore model and interactions in active site of 2D2D	170
Figure 4.76	Alignment of A3 to ENB, shared feature pharmacophore model and interactions in active site of 2D2D	171
Figure 4.77	Alignment of A4 to ENB, shared feature pharmacophore model and interactions in active site of 2D2D	172

Figure 4.78	Alignment of A5 to ENB, shared feature pharmacophore model and interactions in active site of 2D2D	172
Figure 4.79	Alignment of A6 to ENB, shared feature pharmacophore model and interactions in active site of 2D2D	173
Figure 4.80	Alignment of A7 to ENB, shared feature pharmacophore model and interactions in active site of 2D2D	174
Figure 4.81	Unaligned A8 to ENB ligand due to lack of common pharmacophore features	175
Figure 4.82	Unaligned A9 to ENB ligand due to lack of common pharmacophore features	175
Figure 4.83	Route of Schiff base reaction	177
Figure 4.84	FT-IR spectrum of vanillin (Reusch, 2013)	180
Figure 4.85	FT-IR spectrum of A1	183
Figure 4.86	FT-IR spectrum of A2	185
Figure 4.87	FT-IR spectrum of A3	187
Figure 4.88	FT-IR spectrum of A4	189
Figure 4.89	FT-IR spectrum of A5	191
Figure 4.90	FT-IR spectrum of A6	193
Figure 4.91	FT-IR spectrum of A7	195

## LIST OF ABBREVIATIONS

2D	2 Dimensional
3CL <sup>pro</sup>	3C-like Protease
3D	3 Dimensional
CADD	Computer-Aided Drug Design
CDC	Centers for Disease Control and Prevention
COVID-19	Coronavirus Disease 2019
FT-IR	Fourier Transform-Infrared Spectroscopy
HA	Hemagglutinin
HBA	Hydrogen Bond Acceptor
HBD	Hydrogen Bond Donor
LBDD	Ligand-based Drug Design
NA	Neuraminidase
NAIs	Neuraminidase Inhibitors
NI	Negative Ionisable Area
PI	Positive Ionisable Area
PL <sup>pro</sup>	Papain-like Protease
PM	Pharmacophore Model
SARS-CoV	Severe Acute Respiratory Syndrome
SBDD	Structure-based Drug Design
TLC	Thin Layer Chromatography
WHO	World Health Organization